Managers / Q4 2021 · view latest →
MORGAN JESS S & CO INC
CIK 0001133335 · C/O JESS S MORGAN & CO INC, 5900 WILSHIRE BLVD STE 2300, LOS ANGELES, CA, 90036 · 3236342400
Summary
Morgan Jess S & Co Inc reported $163M in U.S.-listed holdings across 46 positions for Q4 2021.
Its largest position, NDQ, represents 5.0% of the portfolio.
Compared with Q3 2021, the fund opened 8 new positions and exited 2.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 54.0% · $88M
- ETP · 41.1% · $67M
- Closed-End Fund · 2.9% · $5M
- Other · 2.0% · $3M
Quarter-over-Quarter Changes full breakdown →
vs Q3 2021 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| WFCWELLS FARGO CO NEW | NEW | +86.2K | 86.2K | +$4M | $4M |
| NVDANVIDIA CORPORATION | NEW | +6.1K | 6.1K | +$2M | $2M |
| MSFTMICROSOFT CORP | NEW | +3.1K | 3.1K | +$1M | $1M |
| INTCINTEL CORP | NEW | +6.0K | 6.0K | +$309,000 | $309,000 |
| LYVLIVE NATION ENTERTAINMENT IN | NEW | +2.5K | 2.5K | +$299,000 | $299,000 |
| CLNNEURCLENE INC | NEW | +29.8K | 29.8K | +$122,000 | $122,000 |
| LCTXLINEAGE CELL THERAPEUTICS IN | NEW | +15.0K | 15.0K | +$37,000 | $37,000 |
| ZSANEURZOSANO PHARMA CORP | NEW | +40.0K | 40.0K | +$19,000 | $19,000 |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q4 2021
Filing History
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.